Background
==========

Subgroups of patients with type 2 diabetes mellitus or features of the metabolic syndrome have been shown to have impaired insulin-dependent whole body glucose uptake \[[@B1]\], the principal component of which is non-oxidative glycogen synthesis in skeletal muscle \[[@B2]\]. Glycogen-synthase (GS) catalyses one of the rate-determining steps in glycogen synthesis in muscle and defective insulin-mediated activation of muscle GS has been found in glucose tolerant, but insulin resistant first-degree relatives of Caucasian type 2 diabetic patients \[[@B3]\]. GS is activated in response to insulin through its net dephosphorylation mediated by inhibition of kinases such as glycogen synthase kinase-3 and activation of glycogen-bound protein phosphatase-1 enzyme in response to insulin \[[@B4]\]. In insulin-resistant Pima Indians decreased activities of both GS and glycogen-associated protein phosphatase-1 in muscle tissue has been demonstrated \[[@B5],[@B6]\] providing a mechanism by which GS activation by insulin is reduced in these subjects.

The most abundant glycogen-associated protein phosphatase-1 (PP-1) derived from skeletal muscle is a heterodimer composed of a 37 kDa ubiquitous catalytic subunit and a 160 kDa glycogen-targeting and regulatory subunit, G~M~\[[@B7]\]. PP1G~M~has been shown to play an important role in the regulation of glycogen synthase activity \[[@B8]\] and may participate in the insulin stimulation of glycogen synthesis \[[@B9]\]. The gene encoding G~M~(*PPP1R3A*) has been located on chromosome 7 \[[@B10]\] in a region in which genome wide scanning in Pima Indians has found markers linked to quantitative traits related to glucose metabolism. Recently a rare premature stop mutation has been detected which produced severe familial insulin resistance when occurring with an unlinked frame shift mutation in a further candidate gene, *PPARG*. \[[@B11]\]. This digenic inheritance serves as a paradigm for the interaction of variation at diverse locations in the genome contributing to the development of the insulin resistant phenotype. Several common variants of *PPP1R3A*have also been variably associated with features of insulin resistance and type 2 diabetes in different populations \[[@B10],[@B12]-[@B17]\]. In particular a 5 bp length insertion deletion polymorphism in the 3\'-untranslated region (UTR) of the gene gives rise to a difference in distance between two AT rich elements (ARE), which have been implicated in mRNA stability \[[@B18],[@B19]\] The deletion variant (allele ARE2) has been found to decrease mRNA half life, and *PPP1R3A*transcript and protein concentrations *in vivo* \[[@B10]\] and displays increased binding of a protein responsible for the increased turnover \[[@B20]\]. Thus, the ARE2 variant has implications for the extent of activation of muscle GS by insulin and hence overall insulin sensitivity. This has recently been confirmed by the deletion of the gene for *PPP1R3A*in mice which results in a markedly insulin resistant phenotype. \[[@B21]\].

The ARE2 allele frequency has been reported to be higher in young type 2 diabetics than a control population in Japan \[[@B12]\] and higher in early diagnosed than late diagnosed type 2 diabetic Pima Indians \[[@B10]\]. In another study ARE2 was weakly associated with whole body insulin sensitivity, with the allele being associated with a trend of higher fasting insulin levels and lower insulin mediated glucose uptake \[[@B15]\]. In contrast a study of aboriginal Canadians showed that ARE2 homozygotes had a lower 2 hour post challenge plasma glucose in type 2 diabetics and individuals with impaired glucose tolerance \[[@B14]\]. Thus the role of the *PPP1R3A*ARE polymorphism in the susceptibility to type 2 diabetes is not clear.

As previous studies have demonstrated an association of the ARE2 variant of *PPP1R3A*with early diagnosed type 2 diabetes and other glycaemic parameters, we have examined its role in such parameters in a genetic sub-study of the Diabetes Audit and Research in Tayside Scotland (DARTS) \[[@B22]\]. In addition we have used a population of local children (aged 5--8) to determine the local gene frequency of the ARE variants at birth, and have examined the divergence from this baseline frequency within the type 2 diabetic population.

Results
=======

We have determined the frequency of the *PPP1R3A*ARE polymorphism in a large group (n = 1950) of approximately equal numbers of men and women with type 2 diabetes in Tayside, Scotland and considered association of genotype with age of diagnosis with type 2 diabetes, glycated haemoglobin and body mass index. 847 (43.4%) were ARE1 homozygotes, 891 (45.7%) ARE1/2 heterozygotes and 212 (10.9%) ARE2 homozygotes. Overall the ARE2 allele frequency was 0.337 (0.322--0.352). ARE genotype demonstrated a strong association with age of diagnosis that was both gene dosage and gender dependent (Table [1](#T1){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). Thus whilst there was no difference between males and females in the mean age of diagnosis for individuals homozygous for the more common ARE1 allele (56.5 years vs 56.7 years respectively), males carrying the less common ARE2 allele (heterozygotes and ARE2 homozygotes) had an earlier mean age of diagnosis (55.1 years) compared with females carrying the ARE2 allele (58.6 years) a difference of 3.6 years which was highly significant (p \< 0.000001). Furthermore female ARE2 carriers were on average 2 years older (p = 0.017) at diagnosis than female ARE1 homozygotes. On the other hand male ARE2 carriers were 1.5 years younger (p = 0.046) at diagnosis compared to male ARE1 homozygotes. Thus males and females who had the ARE2/2 genotype differed in mean age of diagnosis by on average 6.5 years (3.1--9.5, p = 0.0001). Over all there was also a weak association of the rare allele with body mass index after adjustment for age of diagnosis, age of BMI, and treatment, with homozygous ARE2 individuals having a BMI 0.81 lower than ARE1 homozygous individuals (p = 0.041). This association was however confined to females (BMI difference = 1.41, p = 0.021) with males showing no evidence of a difference (p = 0.939). There was also a weak association with glycated haemoglobin in the overall population and again this association was confined to females ARE2 homozygotes who had a glycated haemoglobin on average 1% lower than ARE1 homozygotes (p = 0.047).

![**Age diagnosed with type 2 diabetes in males and females by PPP1R3A ARE genotype.**Legend: Females dashed line open triangle, males solid line closed squares. (Error bars = standard error of the mean)](1471-2156-4-11-1){#F1}

###### 

Characteristics of the Tayside Diabetic population by PPP1R3A genotype and sex. Parameters are given as corrected means ± Standard deviation, the corrected means are based on multiple measures through time and are adjusted for age diagnosed, age at which parameter was measured and drug treatment at time of measurement.

  **Male**                    **ARE1/1**   **ARE1/2**   **ARE2/2**    p value
  --------------------------- ------------ ------------ ------------- -----------------
  **N**                       432          479          111           
  **Age Diagnosed (years)**   56.5 ± 0.6   55.5 ± 0.5   †53.2 ± 1.1   0.008 (0.011\*)
  **BMI (Kg/m^2^)**           29.9 ± 0.2   29.7 ± 0.2   29.9 ± 0.5    NS
  **GHB (%)**                 7.6 ± 0.05   7.5 ± 0.05   7.5 ± 0.1     NS
                                                                      
  **Female**                  **ARE1/1**   **ARE1/2**   **ARE2/2**    p value
                                                                      
  **N**                       415          412          101           
  **Age Diagnosed (years)**   56.7 ± 0.6   58.4 ± 0.6   †59.5 ± 1.2   0.038 (0.2\*)
  **BMI (Kg/m^2^)**           31.6 ± 0.3   31.2 ± 0.3   30.3 ± 0.6    0.021
  **GHB (%)**                 7.8 ± 0.05   7.7 ± 0.05   7.5 ± 0.1     0.047

\* = p value after inclusion of BMI-at-diagnosis in the linear regression model. †p = 0.0001 for comparison between male and female ARE2 homozygotes (recessive model) p \< 0.000001 for a comparison between male and female allele carriers (co-dominant model).

As we found an association of reduced BMI with genotype in females, and increased BMI is known to be the major risk for type 2 diabetes, we included BMI in our regression model for age of diagnosis. This completely removed any significance in the association (Table [1](#T1){ref-type="table"}). Interestingly, inclusion of BMI in the regression model in men did not negate the association with earlier age of diagnosis.

To further explore the association of this polymorphism with gender and age of diagnosis, we compared allele frequencies by gender in individuals diagnosed early and those diagnosed later. Early and later diagnosis were defined as being diagnosed at an age below and above the first quartile of the overall ages at diagnosis respectively. This corresponded to being diagnosed less than or greater than 48.2 years in this population. These frequencies were in turn compared with the background population frequency in a large cohort (495 males, 519 females) of healthy school children from the same region. The overall ARE2 allele frequency in the children was very close to the overall frequency in the diabetic population (Table [2](#T2){ref-type="table"} and figure [2](#F2){ref-type="fig"}). There was no difference in allele frequency between genders in the children (ARE1 allele frequency in males = 0.336, 0.307--0.366 vs. females 0.330, 0.302--0.359). As expected while there was no difference in ARE2 allele frequency between males and females diagnosed later (OR 0.927, 0.793--1.084 p = 0.333) the frequency in early diagnosed males and females was significantly different (OR 1.59, 1.20--2.12 p = 0.0009). The frequency in males was 0.383 (0.342 -- 0.423) which was significantly higher (OR 1.24, 1.015--1.51, p = 0.030) than the background frequency in the children and in early diagnosed females it was 0.280 (0.237 -- 0.324) which was in turn significantly lower (OR 0.78, 0.611--0.991, p = 0.037) than the background frequency in the children. The frequency in the women diagnosed early was also significantly lower than the frequency in those diagnosed later (OR 0.740, 0.576--0.947, p = 0.014). These frequencies were also similarly different in male type 2 diabetics (OR 1.269, 1.030--1.561 p = 0.021).

![**Odds ratios of the ARE2/2 genotype prevalence in type 2 diabetes.**Shown are the Odds Ratios and the 95% confidence intervals.](1471-2156-4-11-2){#F2}

###### 

Genotype and ARE2 allele frequency (with 95% confidence intervals) in men and women diagnosed with early and late diagnosis of type 2 diabetes.

                       **Males**             **Females**           **Children**                                
  -------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
  **ARE11**            106                   326                   104                   311                   457
  **ARE12**            130                   349                   87                    325                   438
  **ARE22**            41                    70                    14                    87                    119
  **Total**            277                   745                   205                   723                   1014
  **ARE2 frequency**   0.383(0.342--0.423)   0.328(0.304--0.352)   0.280(0.237--0.324)   0.345(0.321--0.370)   0.333(0.313--0.354)

Finally, analysis of the ratio of males to females in the total DARTS population and the genetic sub-study (Go-DARTS) showed a marked overall preponderance of early diagnosis for males that is very similar to that observed in previous epidemiological studies (figure [3a](#F3){ref-type="fig"}). This was supported by a χ^2^, test for trend, of 129.9, p \< 0.0001, for the total DARTS population and a χ^2^test for trend of 17.9, p \< 0.0001, in the genotyped subpopulation. This trend resided exclusively in the ARE2 allele carriers with no such trend in ARE1 homozygotes (p = 0.003 for comparison of trends by genotype) (figure [3b](#F3){ref-type="fig"}).

![**Male preponderance in early diagnosis is associated with the ARE2 variant.**A. Ratio of females to males in the total DARTS type 2 population (n= 8155) and in the genotyped subgroup (Go-DARTS, n = 1950) by quintile of age diagnosed B. Ratio of females to males in Go-DARTS by ARE genotype by quintile of age diagnosed. Quintiles were used to maintain equal numbers of individuals in each category and are defined as follows: DARTS: 1=under 48 yrs; 2, 48--56 yrs; 3 = 57--63 yrs; 4 = 64--70 yrs; 5= over 70 yrs. Go-DARTS: 1= under 45 yrs; 2 = 45--54 yrs; 3 = 55--60 yrs; 4 = 60--67 yrs; 5, = over 67 yrs.)](1471-2156-4-11-3){#F3}

Discussion
==========

We have demonstrated that the ARE polymorphism of *PPP1R3A*is associated with age of diagnosis in the Tayside type 2 diabetic population and that this association is both gender and gene dosage dependent. We know from the United Kingdom Prospective Diabetes Study population that there is a preponderance of males at younger ages of diagnosis and that the proportion of men to women decreased at higher ages of diagnosis \[[@B23]\]. We have reproduced this observation in the DARTS population, however this appears to be confined to ARE2 carriers with no such trend being observed in the ARE1 homozygotes. We have also found a weak association of ARE genotype with BMI and glycated haemoglobin which again appears gender dependent with the association being found exclusively in females. Inclusion of BMI in the model for age of diagnosis attenuated its association with genotype in the females which suggests that the ARE2 variant is associated with a protection from obesity-induced diabetes in women. The lack of an attenuation in males indicates that the ARE2 allele may predispose men to type 2 diabetes, in a manner independent of obesity.

The overall frequency of the ARE2 variant obtained in the adult population of individuals with type 2 diabetes is almost identical to the frequency found in the children from the same geographical region and these are similar to other published frequencies in Japanese \[[@B12]\], Caucasian \[[@B15]\] and aboriginal Canadian \[[@B14]\] populations. In the study from the Pima Indians however the frequency was found to be considerably higher \[[@B10]\]. In the Japanese population the mean age of diagnosis was similar to the youngest quartile in our population. Examination of the allele frequencies in the men and women diabetics in this population compared with the control population reveals that the risk of diabetes attributable to the variant was predominantly in the males (0.347 *vs*. 0.288, p = 0.03) and was less evident in the females (0.326 *vs*. 0.288, p = 0.19) \[[@B12]\]. This young-diagnosed population also had a male preponderance similar to that observed in our study. The Pima Indian study which examined the relative risk of diagnosis with type 2 diabetes diagnosis before and after the age of 45 also found a significant predominance of the ARE2 variant in the younger age group \[[@B10]\]. In contrast to our study, and that of the Japanese group, this population had a strong female preponderance. Indeed, it is clear that female Pima Indians are not afforded the protection from early type 2 diabetes that is observed in Caucasian populations, and this is likely to be due to the extremely high prevalence of morbid obesity in these women.

There has only been one published study of any significant size that fails to support the involvement of the ARE polymorphism in type 2 diabetes susceptibility. This study is a prospective study of 696 Swedish men that have been followed for 20 years \[[@B15]\]. Although significant effects of the ARE polymorphism on insulin sensitivity were observed, there was no effect of the ARE polymorphism on incident diagnoses of type 2 diabetes. However, this study recruited at age 50 years, and excluded any individuals with a diagnosis of type 2 diabetes or showed evidence of abnormal glucose homeostasis. This means that the prospective Swedish study excluded exactly the population which demonstrated ARE-related risk, both in our study and in the previous Japanese and Pima studies. Indeed, as our study is an unselected population cohort we reconcile the negative results obtained in the Swedish study, in that the ARE polymorphism is not significantly associated with type 2 diabetes risk in the over 50 s. These results are summarised in table [3](#T3){ref-type="table"} and illustrate how different mixes of sex and age at diagnosis in different case-control studies may modulate observed associations with ARE2 and susceptibility to type 2 diabetes.

###### 

Concordant relationships between this and previous studies regarding ARE variants and type 2 diabetes

  Age at diagnosis   Study                      Sample size (n)   Ethnicity   Sex imbalance   Association of ARE variants with diabetes
  ------------------ -------------------------- ----------------- ----------- --------------- -------------------------------------------
  Younger            Maegawa et al \[[@B12]\]   426               Japanese    Yes             Yes
                     Xia et al \[[@B10]\]       930               Pima        Yes             Yes
                     This study                 482               Caucasian   Yes             Yes
  Later              Hansen et al \[[@B15]\]    696               Caucasian   Yes             No
                     This study                 1,468             Caucasian   No              No

All studies with \>200 diabetic individuals are included, 2 studies were excluded due to small sample size and lack of information regarding age of diagnosis \[[@B14],[@B29]\]. Both of these studies did present significant associations with either disease susceptibility or insulin homeostasis.

It is not possible from the present study to determine the physiological basis of the differences in males and females observed by *PPP1R3A*genotype although it is probable that the differing hormonal environments in pre-menopausal females is a contributing factor. The mean age of menopause in Caucasian women is 50.5 years and the frequency of the ARE2 allele in women was found to rise steadily to about this age after which it plateaus \[data not shown\] to a similar level to that found in the children. It is known that women generally have improved glucose tolerance and increased skeletal muscle sensitivity compared to men \[[@B24]-[@B26]\] Recently it has been demonstrated in both rats and humans that lipid infusions lead to insulin resistance in males but not in females. \[[@B27],[@B28]\] It could be speculated that this variant of the *PPP1R3A*gene plays a role in determining response to the high dietary fat intake in the east of Scotland differentially between males and females although the mechanism for this is obscure at present.

Conclusions
===========

The ARE polymorphism has been associated with susceptibility to type 2 diabetes in several case-control studies. We have shown for the first time using a population-based cohort of unselected individuals with type 2 diabetes that the ARE2 allele is associated with gender selective modulation of the age of diagnosis of type 2 diabetes. This work supports the initial findings that the ARE2 variant modulates susceptibility to type 2 diabetes and indicates an avenue of further investigation for determining physiological basis of gender specific differences in peripheral insulin resistance and onset of type 2 diabetes.

Methods
=======

Tayside Type 2 Diabetic Population
----------------------------------

In Tayside, Scotland detailed clinical information on all individuals with diabetes mellitus is recorded on an electronic clinical information system known as DARTS (Diabetes Audit and Research in Tayside Scotland) which has been described elsewhere \[[@B22]\]. In brief, electronic record linkage techniques have identified all people with diabetes in the population of Tayside with a sensitivity of 97%. All clinical data are recorded according to a standard dataset and all case records are validated by a team of dedicated research nurses who create a \"cradle to the grave\" electronic record. Thus age of diagnosis is rigorously retrospectively determined to coincide with age of onset. All such patients are randomly invited to participate in a genotyping initiative. Following written informed consent, a single sample of blood is collected for DNA extraction and genotyping and the individual assigned a unique system code number for anonymisation purposes. Full compliance with NHS data protection and encryption standards is maintained. Genotype information is stored together with the anonymised clinical information on an SQL database. The population in this study therefore consisted of a free-living clinical population selected only on the basis of having type 2 diabetes and attending a diabetes clinic in Tayside. All subjects were of Caucasian ethnicity. All recorded measures of BMI and percentage glycated haemoglobin together with age at diagnosis for each individual was extracted from the DARTS database.

Tayside Children Population
---------------------------

Healthy school children recruited for a gene/nutrition interaction study in the Tayside region of Scotland were used as a control population in this study. They were \>95% Caucasian and selected at random from local primary schools. Following informed parental consent mouthwash samples were collected for DNA analysis.

DNA analysis
------------

*PPP1R3A*ARE polymorphism was analysed using TaqMan-based allelic discrimination assays on a Applied Biosystems 7700 Sequence Detection System. The oligonucleotides used for this assay were:

Primer 1; CAGATAAAACATGGACAATGGCAG.

Primer 2; GGTTGAAATATTTGATCAATGAATCCTG.

ARE1 PROBE (FAM/TAMRA Labelled):

TGGTCTTTTAGTATTGAACATGAAATTTGTATTTAACACTGTATC.

ARE2 PROBE (TET/TAMRA Labelled)

;TGGTCTTTTAGTATTGAACATGAAATTTGTTCAATTTATCATTTA.

Assays were performed using reagents and conditions as supplied by the manufacturer (Applied Biosystems, Foster City, CA)

Statistics
----------

Allele frequencies were compared using Pearsons\'s Chi Square. Linear regression was used to assess the affect of genotype on Age of Diagnosis. Repeated measures of Body Mass Index and Glycated haemoglobin were used in a repeated measures model which included age diagnosed, age at which parameter was measured and a term for whether the parameter was measured while the individual was on or off drug therapy for type 2 diabetes including insulin. These parameters were normalised by Log10 transformation. All statistical analyses were performed using algorithms available in turbocharged STATA v7. For consideration of gene frequencies by age diagnosed the population was analysed by quartiles and early diagnosis was classified as being within the first quartile of age diagnosed. Chi squared test for trend was used to examine the gender ratios by quintile and logistic regression analysis was used to compare relative frequencies of the females to males over the quintiles by genotype. All ranges stated in the text are 95% confidence intervals.
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